Companies /Healthcare
CRISPR Therapeutics AG
NASDAQ: CRSP Biotechnology
$49.99
▼ $1.43 (−2.78%) today
Markets closed · 6:38pm ET

CRISPR Therapeutics (CRSP) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
29%
EPS beat rate
−12.76%
Avg. EPS surprise
Consecutive EPS misses
CRSP vs Market · 30-day return after each reportCRSPS&P 500
0%+20%+26.2%+7.2%Q1 25−1.3%+3.1%Q2 25+6.4%+1.1%Q3 25−10.1%−3.0%Q4 25−1.0%+1.9%Q1 26+14.8%+1.0%Q2 26
0%+20%Q1 25Q3 25Q1 26
CRSP EPS Trend · estimate vs actualEstimateActual
$-2.10$-1.40$-0.70$-1.28$-1.58Q1 25$-1.40$-2.40Q2 25$-1.29$-1.17Q3 25$-1.23$-1.37Q4 25$-1.23$-1.28Q1 26$-1.18$-0.94Q2 26$-1.06$-1.15Q3 26
$-2.10$-1.40$-0.70Q1 25Q3 25Q1 26Q3 26
CRSP Revenue Trend · estimate vs actualEstimateActual
$0$5.0M$10.0M$15.0M$6.0M$865,000Q1 25$6.4M$892,000Q2 25$9.0M$889,000Q3 25$4.0M$864,000Q4 25$4.3M$1.5MQ1 26$7.4M$10.2MQ2 26$16.6M$12.7MQ3 26
$0$5.0M$10.0M$15.0MQ1 25Q3 25Q1 26Q3 26

How Often Does CRISPR Therapeutics Beat Earnings Estimates?

CRISPR Therapeutics beat EPS estimates in 2 of its last 7 reported quarters.

CRSP quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q3 2026 Includes acquired in-process R&D expense of $11.7 million, primarily a development milestone under the Sirius Agreement $-1.15 est. $-1.06 −8.49% $12.7M est. $16.6M −23.52%
Q2 2026 $-0.94 est. $-1.18 +20.59% $10.2M est. $7.4M +37.03%
Q1 2026 $-1.28 est. $-1.23 −3.68% $1.5M est. $4.3M −65.73%
Q4 2025 $-1.37 est. $-1.23 −11.67% $864,000 est. $4.0M −78.51%
Q3 2025 $-1.17 est. $-1.29 +9.23% $889,000 est. $9.0M −90.07%
Q2 2025 $-2.40 est. $-1.40 −71.55% $892,000 est. $6.4M −86.15%
Q1 2025 $-1.58 est. $-1.28 −23.75% $865,000 est. $6.0M −85.50%

Figures from SEC filings and company reports. Not investment advice.